References
- Turnbull F, Neal B, Algert C, Chalmers J et al; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165, 1410–1419 (2005).
- Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs, results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatments Trials’ Collaborators. Lancet356, 1955–1964 (2000).
- Wang JC, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic lowering as determinants of cardiovascular outcome. Hypertension45, 907–913 (2005).
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality, a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
- Gueyffier F, Bulpitt C, Boissel JP et al.; INDANA group. Antihypertensive drugs in very old people, a subgroup meta-analysis of randomized controlled trials. Lancet353, 793–796 (1999).
- Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med.358, 1887–1898 (2008).
- Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Steward JB. Risks for atrial fibrillation and congestive heart failure in patients over 65 years of age with abnormal ventricular diastolic relaxation. Am. J. Cardiol.93, 54–58 (2004).
- Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart study. Hypertension25, 1155–1160 (1995).
- Tsang TS, Barnes ME, Bailey KR et al. Left atrial volume, important risk marker of incident atrial fibrillation in 1,655 older men and women. Mayo Clin. Proc.76, 467–475 (2001).
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke, the Framingham Study. Stroke22, 983–988 (1991).
- Choudhury A, Lip GYH. Atrial fibrillation and the hypercoagulable state, from basic science to clinical practice. Pathophysiol. Haemost. Thromb.33(5–6), 282–289 (2003/2004).
- Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation, a systematic review. Neurology69, 546–554 (2007).
- Hughes M, Lip GYH. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation, a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost.99, 295–304 (2008).
- Atrial fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotics therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med.154, 1449–1457 (1994).
- Stroke Prevention in Atrial Fibrillation III Writing Committee. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin, Stroke Prevention in Atrial Fibrillation III study. JAMA279, 1273–1277 (1998).
- Lip GYH, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. On behalf of SPORTIF Investigators. Eur. Heart J.28, 752–759 (2007).
- Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure, a combined analysis of three trials. Lancet368, 581–588 (2006).
- Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J. Am. Coll. Cardiol.45, 1832–1839 (2005).
- Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared with Atenolol the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol.45, 712–719 (2005).
- Schmieder R, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hula T. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade, the VALUE trial. J. Hypertens.26(3), 403–411 (2008).